JP2020526584A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526584A5
JP2020526584A5 JP2020522279A JP2020522279A JP2020526584A5 JP 2020526584 A5 JP2020526584 A5 JP 2020526584A5 JP 2020522279 A JP2020522279 A JP 2020522279A JP 2020522279 A JP2020522279 A JP 2020522279A JP 2020526584 A5 JP2020526584 A5 JP 2020526584A5
Authority
JP
Japan
Prior art keywords
seq
cdr2
cdr3
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020522279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526584A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039445 external-priority patent/WO2019005756A1/en
Publication of JP2020526584A publication Critical patent/JP2020526584A/ja
Publication of JP2020526584A5 publication Critical patent/JP2020526584A5/ja
Priority to JP2023088505A priority Critical patent/JP2023116554A/ja
Priority to JP2025013074A priority patent/JP2025069272A/ja
Pending legal-status Critical Current

Links

JP2020522279A 2017-06-28 2018-06-26 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用 Pending JP2020526584A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023088505A JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用
JP2025013074A JP2025069272A (ja) 2017-06-28 2025-01-29 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762525993P 2017-06-28 2017-06-28
US62/525,993 2017-06-28
PCT/US2018/039445 WO2019005756A1 (en) 2017-06-28 2018-06-26 CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088505A Division JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Publications (2)

Publication Number Publication Date
JP2020526584A JP2020526584A (ja) 2020-08-31
JP2020526584A5 true JP2020526584A5 (enExample) 2021-08-05

Family

ID=64742639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020522279A Pending JP2020526584A (ja) 2017-06-28 2018-06-26 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
JP2023088505A Pending JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用
JP2025013074A Withdrawn JP2025069272A (ja) 2017-06-28 2025-01-29 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023088505A Pending JP2023116554A (ja) 2017-06-28 2023-05-30 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用
JP2025013074A Withdrawn JP2025069272A (ja) 2017-06-28 2025-01-29 抗ｍｅｒｔｋアゴニスト抗体－薬物コンジュゲートおよびその使用

Country Status (5)

Country Link
US (2) US11613588B2 (enExample)
EP (1) EP3645041A4 (enExample)
JP (3) JP2020526584A (enExample)
CA (1) CA3068672A1 (enExample)
WO (1) WO2019005756A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645041A4 (en) 2017-06-28 2021-03-17 The Rockefeller University AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES
EP3864046A1 (en) 2018-10-09 2021-08-18 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
CN113874081A (zh) * 2019-02-26 2021-12-31 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
MX2021012692A (es) * 2019-04-19 2021-11-12 Genentech Inc Anticuerpos anti-mertk y sus metodos de uso.
AU2020401319A1 (en) 2019-12-13 2022-06-30 Alector Llc Anti-MerTK antibodies and methods of use thereof
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
US11564989B2 (en) * 2021-01-15 2023-01-31 R.P. Scherer Technologies, Llc Camptothecine antibody-drug conjugates and methods of use thereof
CN117651712A (zh) * 2021-05-14 2024-03-05 茵思博纳公司 Mertk肽及其用途
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
WO2025070337A1 (ja) * 2023-09-25 2025-04-03 アステラス製薬株式会社 抗ＭｅｒＴＫアゴニスト抗体、抗ＭｅｒＴＫ二重特異性抗体、及びその使用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US20080267975A1 (en) 2004-11-24 2008-10-30 The Regents Of The University Of Colorado Mer Diagnostic and Therapeutic Agents
US8415361B2 (en) 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2009140242A1 (en) 2008-05-13 2009-11-19 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
EP2606364A4 (en) 2010-08-19 2014-04-16 Howard Florey Inst TAM RECEPTORS AND TAM RECEPTOR LIGANDS IN THE COLLECTION AND MODULATION OF NEUROPATHOLOGICAL DISEASES
US20150315552A1 (en) * 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
US10221248B2 (en) 2014-12-22 2019-03-05 The Rockefeller University Anti-MERTK agonistic antibodies and uses thereof
EP3645041A4 (en) 2017-06-28 2021-03-17 The Rockefeller University AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES
CN113874081A (zh) * 2019-02-26 2021-12-31 茵思博纳公司 高-亲和力抗-mertk抗体及其用途

Similar Documents

Publication Publication Date Title
JP2020526584A5 (enExample)
FI3930847T3 (fi) Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
JP2022101693A5 (enExample)
JP2023022328A5 (enExample)
RU2483080C2 (ru) Антитела и иммуноконъюгаты и их применение
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
HRP20200283T1 (hr) Protutijela koja se vežu na axl
HRP20171789T1 (hr) Konjugati humanog protutijela s lijekom protiv tkivnog faktora
JP2012522513A5 (enExample)
JP2020502271A5 (enExample)
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
HRP20220172T1 (hr) Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe
JP2012522512A5 (enExample)
JP2018520991A5 (enExample)
JP2019532056A5 (enExample)
RU2008141171A (ru) Анти-тат226 антитела и иммуноконъюгаты
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
JP2014520088A5 (enExample)
JP2010535713A5 (enExample)
WO2022228563A1 (zh) 靶向Nectin-4的抗体药物偶联物及其制备方法和用途
JP2018501781A5 (enExample)
JP2014522850A5 (enExample)
JP2017522871A5 (enExample)
JP2016538318A5 (enExample)
JPWO2021213434A5 (enExample)